Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
- Saint Luke's Cancer Institute - Boise — Boise, Idaho
- Kootenai Health - Coeur d'Alene — Coeur d'Alene, Idaho
- Saint Luke's Cancer Institute - Fruitland — Fruitland, Idaho
- Saint Luke's Cancer Institute - Meridian — Meridian, Idaho
- Saint Luke's Cancer Institute - Nampa — Nampa, Idaho